help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gaasenbeek, M.
Right arrow Articles by McCarthy, M. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gaasenbeek, M.
Right arrow Articles by McCarthy, M. I.
The Journal of Clinical Endocrinology & Metabolism Vol. 89, No. 5 2408-2413
Copyright © 2004 by The Endocrine Society

Large-Scale Analysis of the Relationship between CYP11A Promoter Variation, Polycystic Ovarian Syndrome, and Serum Testosterone

Michelle Gaasenbeek, Brenda L. Powell, Ulla Sovio, Lema Haddad, Neda Gharani, Amanda Bennett, Christopher J. Groves, Karen Rush, Micaela J. Goh, Gerard S. Conway, Aimo Ruokonen, Hannu Martikainen, Anneli Pouta, Saara Taponen, Anna-Liisa Hartikainen, Stephanie Halford, Marjo-Riitta Järvelin, Steve Franks and Mark I. McCarthy

Genomic Medicine, Faculty of Medicine (M.G., L.H., N.G., A.B., S.H., M.I.M.) and Institute of Reproductive and Developmental Biology (M.G., S.F.), Imperial College, Hammersmith Campus, London W12 0NN, United Kingdom; Departments of Epidemiology and Public Health (U.S., M.-R.J.) and Reproductive Endocrinology (K.R., M.J.G., S.F.), Imperial College, St. Mary’s Campus, London W2 1PG, United Kingdom; Wellcome Trust Centre for Human Genetics (B.L.P., C.J.G., M.I.M.) and Oxford Centre for Diabetes, Endocrinology and Metabolism (B.L.P., A.B., C.J.G., M.I.M.), Churchill Hospital, Oxford OX3 7LJ, United Kingdom; Department of Obstetrics and Gynaecology (G.S.C.), Bloomsbury Site, University College, London WC1E 6BT, United Kingdom; and Departments of Clinical Chemistry (A.R., S.T.), Obstetrics and Gynecology (S.T., H.M., A.-L.H.), and Public Health Science and General Practice (M.-R.J., S.T., A.P.), University of Oulu, Oulu, Finland 90014

Address all correspondence and requests for reprints to: Prof. Mark McCarthy, Robert Turner Professor of Diabetes, Oxford Centre for Diabetes, Endocrinology & Metabolism, Churchill Hospital Site, Old Road, Headington, Oxford OX3 7LJ, United Kingdom. E-mail: Mark.mccarthy{at}drl.ox.ac.uk.

CYP11A, the gene encoding P450scc, a key enzyme in steroid biosynthesis, is a strong biological candidate for polycystic ovary syndrome (PCOS) susceptibility. Four of the five published studies that have examined CYP11A for evidence of linkage and/or association have reported significant relationships with polycystic ovary (PCO) status and/or serum testosterone levels. However, study sizes have been modest, and the current study aimed to reevaluate these findings using significantly larger clinical resources. A pair of CYP11A promoter microsatellites, including the pentanucleotide (D15S520) previously implicated in trait susceptibility, were genotyped in 371 PCOS patients of United Kingdom origin, using both case-control and family-based association methods, and in 1589 women from a population-based birth cohort from Finland characterized for PCO symptomatology and testosterone levels. Although nominally significant differences in allele and genotype frequencies at both loci were observed in the United Kingdom case-control study (for example, an excess of the pentanucleotide four-repeat allele in cases, P = 0.005), these findings were not substantiated in the other analyses, and no discernable relationship was seen between variation at these loci and serum testosterone levels. These studies indicate that the strength of, and indeed the existence of, associations between CYP11A promoter variation and androgen-related phenotypes has been substantially overestimated in previous studies.

This work was supported by the United Kingdom Medical Research Council (Program Grant G9700120), the Academy of Finland, the European Commission (Framework 5 Award QLG1-CT-2000-01643), and the Wellcome Trust (Project Grant GR069224MA).

Abbreviations: PCO, Polycystic ovary; PCOS, PCO syndrome; USS, ultrasound scan.




This article has been cited by other articles:


Home page
Hum Reprod UpdateHome page
M. Simoni, C.B. Tempfer, B. Destenaves, and B.C.J.M. Fauser
Functional genetic polymorphisms and female reproductive disorders: Part I: polycystic ovary syndrome and ovarian response
Hum. Reprod. Update, September 1, 2008; 14(5): 459 - 484.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
L. C. Sakoda, C. Blackston, J. A. Doherty, R. M. Ray, M. G. Lin, H. Stalsberg, D. L. Gao, Z. Feng, D. B. Thomas, and C. Chen
Polymorphisms in Steroid Hormone Biosynthesis Genes and Risk of Breast Cancer and Fibrocystic Breast Conditions in Chinese Women
Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1066 - 1073.
[Abstract] [Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
The ESHRE Capri Workshop Group
Genetic aspects of female reproduction
Hum. Reprod. Update, April 2, 2008; (2008) dmn009v1.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. O. Goodarzi, M. R. Jones, H. J. Antoine, M. Pall, Y.-D. I. Chen, and R. Azziz
Nonreplication of the Type 5 17 -Hydroxysteroid Dehydrogenase Gene Association with Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 300 - 303.
[Abstract] [Full Text] [PDF]


Home page
Am J EpidemiolHome page
S. H. Olson, E. V. Bandera, and I. Orlow
Variants in Estrogen Biosynthesis Genes, Sex Steroid Hormone Levels, and Endometrial Cancer: A HuGE Review
Am. J. Epidemiol., February 1, 2007; 165(3): 235 - 245.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
V. W. Setiawan, I. Cheng, D. O. Stram, E. Giorgi, M. C. Pike, D. Van Den Berg, L. Pooler, N. P. Burtt, L. Le Marchand, D. Altshuler, et al.
A Systematic Assessment of Common Genetic Variation in CYP11A and Risk of Breast Cancer
Cancer Res., December 15, 2006; 66(24): 12019 - 12025.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
J. M. Vink, S. Sadrzadeh, C. B. Lambalk, and D. I. Boomsma
Heritability of Polycystic Ovary Syndrome in a Dutch Twin-Family Study
J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2100 - 2104.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
N. Xita and A. Tsatsoulis
Fetal Programming of Polycystic Ovary Syndrome by Androgen Excess: Evidence from Experimental, Clinical, and Genetic Association Studies
J. Clin. Endocrinol. Metab., May 1, 2006; 91(5): 1660 - 1666.
[Abstract] [Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
D.H. Abbott, D.K. Barnett, C.M. Bruns, and D.A. Dumesic
Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome?
Hum. Reprod. Update, July 1, 2005; 11(4): 357 - 374.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
H. F. Escobar-Morreale, M. Luque-Ramirez, and J. L. San Millan
The Molecular-Genetic Basis of Functional Hyperandrogenism and the Polycystic Ovary Syndrome
Endocr. Rev., April 1, 2005; 26(2): 251 - 282.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
D. A. Ehrmann
Polycystic Ovary Syndrome
N. Engl. J. Med., March 24, 2005; 352(12): 1223 - 1236.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2004 by The Endocrine Society